In this section
@article{Valente:2024:10.1136/bmjgh-2024-015402,
author = {Valente, de Almeida S and Hauck, K and Njenga, S and Nugrahani, Y and Ayu, R and Mawaddati, R and Saputra, S and Hasnida, A and Pisani, E and Anggriani, Y and Gheorghe, A},
doi = {10.1136/bmjgh-2024-015402},
journal = {BMJ Global Health},
title = {Value for money of medicine sampling and quality testing: evidence from Indonesia},
url = {http://dx.doi.org/10.1136/bmjgh-2024-015402},
volume = {9},
year = {2024}
}
TY - JOUR
AB - Background Substandard and falsified medicines (SFMs) are a public health concern of global importance. Postmarket surveillance in the form of medicine sampling and quality testing can prevent and detect SFM, however, there is remarkably scarce evidence about the cost and value for money of these activities: how much do they cost and how effective are they in detecting SFM?Methods Between February and October 2022, Systematic Tracking of At Risk Medicines (STARmeds) collected and analysed for quality 1274 samples of 5 medicines from physical and online retail outlets in 7 Indonesian districts. We collated data on the resources consumed by STARmeds, related to all stages of medicines sampling and quality testing including design, fieldwork and laboratory analysis. We used activity-based costing principles to calculate the financial and economic cost of medicine quality surveillance from the perspective of a hypothetical medicines’ regulator. We calculated the cost per day and per week of fieldwork, per sample collected and per substandard sample. We used bootstrapping to capture uncertainty in the number of samples collected, by seller location type (urban, rural and online).Results The total cost of sampling and testing medicines from the market was US$712 964 (current 2022 values). Laboratory costs represented the largest share (70%), followed by other direct costs (12%) and indirect costs (7%). On average, it costs STARmeds US$479 (95% CI US$462 to US$516) to collect one medicine sample and US$5990 (95% CI US$5601 to US$6258) to identify one substandard sample.Conclusion Our findings bring urgently needed and novel information on the cost and value for money of medicine quality surveillance. These may support planning and budgeting of the Indonesian pharmaceutical regulator, but also of regulators and researchers elsewhere, particularly in low-income and middle-income settings, as well as international organisations with health regulation and quality of care
AU - Valente,de Almeida S
AU - Hauck,K
AU - Njenga,S
AU - Nugrahani,Y
AU - Ayu,R
AU - Mawaddati,R
AU - Saputra,S
AU - Hasnida,A
AU - Pisani,E
AU - Anggriani,Y
AU - Gheorghe,A
DO - 10.1136/bmjgh-2024-015402
PY - 2024///
SN - 2059-7908
TI - Value for money of medicine sampling and quality testing: evidence from Indonesia
T2 - BMJ Global Health
UR - http://dx.doi.org/10.1136/bmjgh-2024-015402
UR - https://gh.bmj.com/content/9/9/e015402
UR - http://hdl.handle.net/10044/1/114311
VL - 9
ER -
For any enquiries related to the MRC Centre please contact:
Scientific Manager
Susannah Fisher
mrc.gida@imperial.ac.uk
External Relationships and Communications Manager
Dr Sabine van Elsland
s.van-elsland@imperial.ac.uk